Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys

Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats

(2016) Scott Taylor et al.   BONE

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

(2016) Felicia Cosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study

(2016) Luc Chouinard et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

(2015) Christopher P Recknor et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

(2015) Robert R. Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody

(2014) Xiaodong Li et al.   ENDOCRINOLOGY

Bone Matrix Quality After Sclerostin Antibody Treatment

(2014) Ryan D Ross et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

(2014) Michael R. McClung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody

(2013) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases

(2012) Hua Zhu Ke et al.   ENDOCRINE REVIEWS

Absence of sclerostin adversely affects B-cell survival

(2012) Corey J Cain et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)2d3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone

(2010) R.W. Boyce et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

(2010) Desmond Padhi et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1–34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys

(2010) M. Saito et al.   OSTEOPOROSIS INTERNATIONAL

Skeletal health: primate model of postmenopausal osteoporosis

(2009) S.Y. Smith et al.   AMERICAN JOURNAL OF PRIMATOLOGY

Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1–84

(2008) M.A. Miller et al.   BONE

Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*

(2008) Xiaodong Li et al.   JOURNAL OF BONE AND MINERAL RESEARCH